NCT00484185View on ClinicalTrials.gov

Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B

CompletedOBSERVATIONAL
Enrollment

183

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Hemophilia B
Interventions
DRUG

BeneFIX (coagulation factor IX (recombinant))

BeneFIX will be administered according to physician's discretion.

Trial Locations (1)

137-882

Pfizer Investigational Site, Seoul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY